Journal Article

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis

Thézénas, Marie Laëtitia, Charles, Philip D, Samsonova, Anastasia, Fischer, Roman, Rahman, Najib M, Schiller, Herbert B, Asciak, Rachelle, Pass, Harvey I, Mercer, Rachel, Stathopoulos, Georgios T, Collins, Gary S, Kessler, Benedikt M, Gerry, Stephen, Maskell, Nick, Dong, Tao, Kanellakis, Nikolaos I, Dobson, Melissa, Pavord, Ian D, Hallifax, Robert J, Psallidas, Ioannis

2018

Overview

The prevalence of malignant pleural effusion is increasing worldwide, but prognostic biomarkers to plan treatment and to understand the underlying mechanisms of disease progression remain unidentified. The PROMISE study was designed with the objectives to discover, validate, and prospectively assess biomarkers of survival and pleurodesis response in malignant pleural effusion and build a score that predicts survival. In this multicohort study, we used five separate and independent datasets from randomised controlled trials to investigate potential biomarkers of survival and pleurodesis. Mass spectrometry-based discovery was used to investigate pleural fluid samples for differential protein expression in patients from the discovery group with different survival and pleurodesis outcomes. Clinical, radiological, and biological variables were entered into least absolute shrinkage and selection operator regression to build a model that predicts 3-month mortality. We evaluated the model using internal and external validation. 17 biomarker candidates of survival and seven of pleurodesis were identified in the discovery dataset. Three independent datasets (n=502) were used for biomarker validation. All pleurodesis biomarkers failed, and gelsolin, macrophage migration inhibitory factor, versican, and tissue inhibitor of metalloproteinases 1 (TIMP1) emerged as accurate predictors of survival. Eight variables (haemoglobin, C-reactive protein, white blood cell count, Eastern Cooperative Oncology Group performance status, cancer type, pleural fluid TIMP1 concentrations, and previous chemotherapy or radiotherapy) were validated and used to develop a survival score. Internal validation with bootstrap resampling and external validation with 162 patients from two independent datasets showed good discrimination (C statistic values of 0·78 [95% CI 0·72–0·83] for internal validation and 0·89 [0·84–0·93] for external validation of the clinical PROMISE score). To our knowledge, the PROMISE score is the first prospectively validated prognostic model for malignant pleural effusion that combines biological and clinical parameters to accurately estimate 3-month mortality. It is a robust, clinically relevant prognostic score that can be applied immediately, provide important information on patient prognosis, and guide the selection of appropriate management strategies. European Respiratory Society, Medical Research Funding-University of Oxford, Slater & Gordon Research Fund, and Oxfordshire Health Services Research Committee Research Grants.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Adult / Aged / Biomarkers / Biomarkers - blood / Blood / C-reactive protein / Cancer / Cancer therapies / Cause of Death / Chemotherapy / Clinical trials / Cohort Studies / Databases, Factual / Ethics / Female / Gelsolin / Hematology, Oncology, and Palliative Medicine / Hemoglobin / Humans / Leukocyte migration / Macrophage migration inhibitory factor / Male / Mass spectroscopy / Medical prognosis / Medical research / Mesothelioma / Middle Aged / Mortality / Patients / Pleural effusion / Pleural Effusion, Malignant - blood / Pleural Effusion, Malignant - mortality / Pleural Effusion, Malignant - therapy / Pleural fluid / Pleurodesis - methods / Pleurodesis - mortality / Predictive Value of Tests / Prognosis / Proteins / Radiation therapy / Regulatory approval / Reproducibility of Results / Retrospective Studies / Risk Assessment / Severity of Illness Index / Studies / Survival Analysis / Tissue inhibitor of metalloproteinase 1 / Treatment Outcome / Versican